Summit Creek Advisors LLC Acquires New Position in BioLife Solutions, Inc. $BLFS
Summit Creek Advisors LLC has acquired a new position in BioLife Solutions, Inc. (NASDAQ:BLFS) during the second quarter, purchasing 180,544 shares valued at approximately $5.1 million, making BLFS its 28th largest position. Institutional investors and hedge funds collectively own 93.24% of the company, though analyst sentiment remains mixed with an average "Hold" rating. BioLife Solutions recently reported strong quarterly EPS of $0.91, significantly exceeding estimates, while facing insider selling from a major shareholder.
Diamond Hill Capital Management LLC Investment Advisor Acquires New Stake in BioLife Solutions, Inc. $BLFS
Diamond Hill Capital Management LLC Investment Advisor has acquired a new stake of 153,887 shares in BioLife Solutions, Inc. (NASDAQ:BLFS), valued at approximately $4.35 million. This purchase represents 0.31% of BioLife Solutions, with institutional investors now owning 93.24% of the company. Despite BioLife Solutions beating analysts' EPS and revenue estimates in its latest quarterly report, the consensus analyst rating for the stock has shifted to "Hold" with a target price of $31.38.
Short Interest in BioLife Solutions, Inc. (NASDAQ:BLFS) Rises By 59.1%
Short interest in BioLife Solutions (NASDAQ:BLFS) surged by 59.1% in July, reaching 4.54 million shares, which represents 9.5% of its outstanding shares. This increase comes as analysts have become more cautious, with several downgrading the stock to "Hold" or "Neutral" and reducing price targets to around $31. Despite these concerns, BioLife Solutions recently surpassed quarterly earnings and revenue expectations.
Biolife Solutions stock hits 52-week high at 35.36 USD
BioLife Solutions Inc. (BLFS) has reached a new 52-week high of $35.36, representing a significant surge of nearly 98% from its 52-week low, driven by strong investor confidence. Despite this, InvestingPro data suggests the stock is currently in overbought territory and appears overvalued according to its Fair Value analysis. Additionally, TD Cowen recently downgraded BioLife Solutions to a Hold rating following Repligen's announcement to acquire the company for $31 per share.
BioLife’s Sharp Swing To Profit Might Change The Case For Investing In BioLife Solutions (BLFS)
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss to a net income of US$45.10 million and improving EPS from a loss of US$0.32 to earnings of US$0.92. This sharp increase in profitability, coupled with the pending US$1.6 billion acquisition by Repligen, could reshape the company's investment profile. However, investors should also consider the business's reliance on a concentrated customer base and the long-term demand for cell and gene therapy tools.
Roubaix Capital, LLC's BioLife Solutions Inc(BLFS) Holding History
This article details Roubaix Capital, LLC's investment history in BioLife Solutions Inc (BLFS). As of June 30, 2026, Roubaix Capital held over 309,000 shares of BLFS, valued at $8.74 million, representing 3.14% of their portfolio. The firm has made multiple purchases and sales of BLFS since 2019, resulting in an estimated gain of $4.38 million.
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of "Hold" by Brokerages
BioLife Solutions (NASDAQ:BLFS) has received an average "Hold" recommendation from brokerages, with the majority of analysts issuing a hold rating. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite positive institutional investor activity, insiders have sold a significant number of shares in the last quarter.
BioLife Solutions, Inc. (BLFS) Stock Forecasts
Argus has raised its target price for BioLife Solutions Inc. (BLFS) to $37.00. The company, a life sciences firm, specializes in bioproduction products and services aimed at enhancing quality and mitigating risks in biologic manufacturing, distribution, and transportation within the cell and gene therapy industry. This update suggests a positive outlook for BLFS by Argus.
BioLife Solutions (NASDAQ:BLFS) Hits New 12-Month High - Time to Buy?
BioLife Solutions (NASDAQ:BLFS) recently hit a new 52-week high of $34.93, trading nearly flat at $34.64. The company reported strong quarterly earnings of $0.91 per share, significantly beating the consensus estimate of $0.03, and revenue of $28.47 million, exceeding expectations. Despite insider selling activity totaling $28.1 million over the last quarter, institutional investors hold a substantial 93.24% stake in the company, with analyst sentiment generally mixed, holding a consensus "Hold" rating and a target price below the current share price.
BioLife Solutions Cut to Hold From Buy by Benchmark
Benchmark downgraded BioLife Solutions (BLFS) stock from Buy to Hold. This adjustment reflects a revised outlook from the firm regarding the company's investment potential.
Why BioLife Solutions (BLFS) Is Up 7.8% After Swinging To Q2 Profitability And What's Next
BioLife Solutions (BLFS) reported a significant swing to profitability in Q2 2026, with sales up to US$28.47 million and net income of US$45.1 million, driven by its role as a supplier to the cell and gene therapy sector. The company is set to be acquired by Repligen for US$1.6 billion, a deal expected to close in Q4 2026. This financial improvement and the impending acquisition reframe its investment outlook, though risks like customer concentration remain.
BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss of US$15.84 million to a net income of US$45.10 million, with sales increasing to US$28.47 million. This improved financial performance follows the announcement of a US$1.6 billion acquisition by Repligen, shifting the company's immediate focus towards deal completion and integration. Despite the strong quarter, the article highlights the importance of customer concentration and execution on new products as key short-term factors, with analysts giving varied fair value estimates for the stock.
BioLife Solutions, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioLife Solutions, Inc. has released its earnings summary for the quarter that ended on June 30. The full article provides detailed results of the company's financial performance during this period.
ETFs Investing in BioLife Solutions, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of BioLife Solutions, Inc. (BLFS). The ETFs are primarily focused on small-cap companies and are managed by various financial institutions like BlackRock, State Street Corp., and The Vanguard Group. The provided table includes details such as market value, weight of BLFS stock in the fund, issuer, management style, expense ratio, assets under management (AUM), and historical performance.
Royal Bank of Canada Purchases 66,010 Shares of BioLife Solutions, Inc. $BLFS
Royal Bank of Canada increased its stake in BioLife Solutions (NASDAQ:BLFS) by 8.1%, purchasing an additional 66,010 shares, bringing its total to 885,298 shares valued at approximately $16.9 million. This transaction comes as other institutional investors have adjusted their positions, and despite a major insider sale, BioLife Solutions reported quarterly earnings per share of $0.04, beating estimates. Analysts maintain a "Hold" rating with a consensus target price of $31.38, while the stock trades at $33.93.
BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss to a profit of US$45.10 million on US$28.47 million in sales. This positive financial performance comes shortly after the announcement of its US$1.6 billion acquisition by Repligen. The article highlights that while the improved earnings are positive, risks such as customer concentration and execution on new products remain, and the acquisition shifts the focus to deal completion and integration.
BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen
BioLife Solutions (NASDAQ: BLFS) has reported strong Q2 2026 financial results, with revenue reaching $28.5 million and net income from continuing operations at $45.1 million, largely due to a significant income tax benefit. The company also announced a cash-and-stock merger agreement with Repligen, where each BioLife share will be exchanged for $11.25 in cash and 0.1442 Repligen shares, with the merger expected to close in Q4 2026. This move follows BioLife's recent divestiture of its SAVSU business and aims to integrate its bioproduction products and services into Repligen's operations.
Earnings Flash (BLFS) BioLife Solutions, Inc. Reports Q2 Revenue $28.5M, vs. FactSet Est of $27.8M
BioLife Solutions, Inc. (BLFS) announced its Q2 revenue of $28.5 million, surpassing the FactSet estimate of $27.8 million. The company's stock, listed on Nasdaq, closed at $33.93 on August 6th, marking a 0.38% increase for the day. This positive earnings report follows a series of recent downgrades from several analysts and an acquisition agreement by Repligen Corporation for approximately $1.6 billion.
BioLife Solutions Reports Second Quarter 2026 Financial Results
BioLife Solutions announced its Q2 2026 financial results, reporting total revenue of $28.5 million, a 21% increase over Q2 2025, and GAAP net income of $45.1 million, which included a significant non-cash income tax benefit. The company also confirmed its pending acquisition by Repligen for approximately $1.5 billion, expected to close in Q4 2026. This acquisition will result in BioLife ceasing to be a publicly traded company.
BioLife Solutions set to report earnings under takeover cloud
BioLife Solutions is set to report second-quarter earnings under the shadow of a $1.5 billion acquisition agreement by Repligen Corporation. Analysts have largely downgraded BioLife's stock to "Hold" with price targets around the acquisition price of $31 per share. Investors will be focused on whether the earnings validate Repligen's valuation and any updates on the deal's closure, which is expected in Q4 2026.
Biolife Solutions stock hits 52-week high at 33.18 USD
BioLife Solutions Inc. (NASDAQ:BLFS) stock recently hit a 52-week high of $33.18, reflecting a 56.33% increase over the past year and a current market capitalization of $1.61 billion. Despite strong revenue growth and analyst predictions of profitability, InvestingPro analysis suggests the stock may be overvalued. Additionally, Repligen announced plans to acquire BioLife Solutions for $31 per share, leading to a downgrade from TD Cowen.
Repligen Corporation (BLFS) sets cash and stock terms for BioLife Solutions buyout
Repligen Corporation has entered into an Agreement and Plan of Merger to acquire BioLife Solutions for $11.25 in cash plus 0.1442 shares of Repligen common stock per BioLife share. The transaction is a strategic move in the cell therapy market, pending regulatory and BioLife stockholder approvals, with an expected closing in Q4 2026. Repligen plans to file a Form S-4 registration statement, including a joint proxy statement/prospectus, for BioLife stockholders to review.
Repligen to acquire BioLife Solutions in two-step merger; employee video details timeline
BioLife Solutions and Repligen are set to merge through a two-step process, forming a Repligen subsidiary, with an expected closing in Q4 pending approvals. The first step involves Repligen's Merger Sub 1 merging into BioLife, making BioLife a direct subsidiary, followed immediately by BioLife merging into Merger Sub 2. Repligen's CEO shared a video with BioLife staff detailing the strategic rationale and cultural fit.
BioLife Solutions, Inc. Revenue Breakdown – NASDAQ:BLFS
This article provides a revenue breakdown for BioLife Solutions, Inc. (NASDAQ: BLFS). Last year, the company generated $96.21 million USD, with its top-performing segment, Bioproduction Products and Services, contributing the entire amount. The United States was the primary revenue source, accounting for $76.97 million USD last year.
BioLife Solutions Inc (BLFS) Valuation: PE, PB & Fair Value Analysis
BioLife Solutions Inc (BLFS) currently has a valuation score of 8.75, placing it 62nd out of 199 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -508.27, which is significantly below its recent high and slightly above its recent low. Other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Hsbc Holdings PLC Purchases Shares of 45,576 BioLife Solutions, Inc. $BLFS
HSBC Holdings PLC has acquired 45,576 shares of BioLife Solutions, Inc. (NASDAQ:BLFS) valued at about $874,000, representing a 0.09% stake in the medical equipment provider. Despite the company recently exceeding earnings expectations with $0.04 EPS versus a $0.01 estimate and $27.50 million in revenue, analysts have mostly downgraded the stock to a "Hold" rating with a consensus price target of $31.38. This comes amidst significant insider selling, with 1.2 million shares worth approximately $28.1 million offloaded in the past 90 days.
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
This article summarizes changes in analyst ratings and price targets for several U.S.-listed companies as reported by Reuters on a Friday. Key changes include Stephens cutting BioLife Solutions to equal weight, Leerink Partners raising Gossamer Bio to outperform, and TD Cowen cutting Intuit to hold. Additionally, JP Morgan raised International Paper to overweight, and Canaccord Genuity cut MapLight Therapeutics' target price.
Repligen (RGEN) Held An M&A Call With BioLife Solutions.
Repligen and BioLife Solutions recently held an M&A call to discuss potential combinations or partnerships in bioprocessing and cell and gene therapy tools. This new corporate activity comes as Repligen's shares show mixed returns, and investors will be looking for clarity on deal structure, integration plans, and the impact on strategic priorities. The article highlights the risks and rewards, including integration challenges and expanded product portfolios, that investors should consider.
Biolife Solutions stock hits 52-week high at 32.24 USD By Investing.com
BioLife Solutions (BLFS) recently reached a 52-week high of $32.24, highlighting a significant upward trend with a 34.8% stock price increase over the last year. However, despite impressive Q1 2026 revenue growth and a "GREAT" financial health score from InvestingPro, data suggests the stock might be overvalued. The company is also set to be acquired by Repligen (RGEN) for $31 per share, leading to a downgrade from Buy to Hold by TD Cowen.
BioLife Solutions, Inc. (BLFS) Investor Outlook: Navigating Growth with a 4.9% Upside Potential
BioLife Solutions, Inc. (BLFS) is a healthcare company specializing in medical instruments and supplies for cell and gene therapy, with a market cap of $1.46 billion. Despite a current EPS of -0.24 and negative return on equity due to ongoing investments, analysts project a 4.9% upside potential from its current share price of $29.79, with an average target of $31.25. The company exhibits strong revenue growth of 24.70% and positive technical indicators, and analyst sentiment is cautiously optimistic with 3 buy ratings and 6 hold ratings.
Biolife Solutions stock hits 52-week high at 32.24 USD
Biolife Solutions stock reached a 52-week high of $32.24, showing a significant 34.8% increase over the past year. The company boasts a 1.56 billion USD market cap, nearly 30% revenue growth, and a "GREAT" financial health score from InvestingPro, though its stock may be overvalued by InvestingPro's Fair Value analysis. Additionally, Repligen plans to acquire BioLife Solutions for $31 per share, leading TD Cowen to downgrade the stock from Buy to Hold.
HC Wainwright Expects Higher Earnings for BioLife Solutions
HC Wainwright has increased its Q2 2026 EPS forecast for BioLife Solutions to a loss of $0.01, up from a projected loss of $0.02, while maintaining a Neutral rating and $31 price target. The company reported quarterly EPS of $0.04, surpassing estimates, but insider sales of 1.2 million shares worth $28.1 million have occurred recently. Analyst sentiment for BioLife Solutions remains cautious, with an average "Hold" rating and a consensus target price of $31.43.
BioLife Solutions Inc (BLFS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for BioLife Solutions Inc (BLFS), detailing its regional revenue contributions. As of April 6, the company generated $76.97 million (80%) from the United States, $13.47 million (14%) from Europe & Middle East & Africa (EMEA), and $5.77 million (6%) from other countries. Information regarding revenue by business segment and profit contribution is not yet disclosed.
BioLife Solutions, Inc. Revenue Breakdown – GETTEX:BJX1
BioLife Solutions, Inc. (GETTEX: BJX1) reported a total revenue of €81.92 million last year, primarily from its Bioproduction Products and Services segment. The majority of this revenue, €65.53 million, was generated in the United States. The article provides a breakdown of the company's financial performance by segments and geographic regions.
BioLife Solutions (BLFS) Faces Fairness Probes After Repligen Agrees To Buy It
BioLife Solutions (BLFS) is facing fairness probes from several law firms after Repligen agreed to acquire the company. The investigations focus on ensuring the transaction terms are fair to BioLife Solutions shareholders, considering the agreed US$31.00 per share price which includes a mix of stock and cash. Shareholders will need to monitor proxy filings, regulatory reviews, and potential revised bids as the merger progresses.
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). KSF is concerned that the offered consideration of $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share may undervalue the company. The firm encourages BioLife shareholders who believe the transaction undervalues the company to contact them to discuss their legal rights.
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal
Repligen is acquiring BioLife Solutions (BLFS) in a cash-and-stock deal valued at approximately $1.5 billion, with BioLife shareholders receiving $11.25 cash and 0.1442 Repligen shares per BioLife share. The acquisition aims to strengthen Repligen's position in the rapidly growing cell therapy market, leveraging BioLife's leading cryopreservation media and cell processing tools. Repligen expects the deal to be accretive to revenue growth, margins, and adjusted EPS from year one, projecting significant synergies and a strong return on invested capital.
BioLife Solutions, Inc. (BLFS) Stock Forecasts
The provided content is an error page from Yahoo Finance, indicating that something went wrong while attempting to display information related to BioLife Solutions, Inc. (BLFS) stock forecasts. It does not contain any actual article text, financial data, or stock-related research. The page primarily consists of navigation links and general website information.
BIOLIFE SOLUTIONS INC : JEFFERIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $31 FROM $30
Jefferies has changed its rating for Biolife Solutions Inc. (BLFS.O) from "buy" to "hold." Despite the downgrade, the investment bank increased its target price for the company's stock to $31 from its previous estimate of $30. This adjustment reflects a nuanced view from Jefferies on Biolife Solutions' future performance.
BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal
BioLife Solutions, a Bothell, Wash.-based company specializing in tools for cell and gene therapy, is set to be acquired by Repligen, a life sciences corporation, for $1.5 billion. The deal involves BioLife shareholders receiving $11.25 in cash plus 0.1442 shares of Repligen stock per share, totaling $31 per share. Both companies, launched in the 1980s, play crucial roles in advanced medical treatments: BioLife provides biopreservation media, while Repligen manufactures materials for biological therapies.
BioLife Solutions Inc
Repligen Corp announced its intent to acquire BioLife Solutions in a cash-and-stock deal valued at approximately $1.5 billion. This acquisition is aimed at expanding Repligen's presence in the rapidly growing cell therapy market. The deal positions Repligen to capitalize on the increasing demand for drugmaking equipment in this sector.
Goodwin Advises Repligen In Acquisition Of BioLife Solutions For Approximately $1.5 Billion
Goodwin Procter LLP advised Repligen Corporation in its definitive agreement to acquire BioLife Solutions, Inc., for approximately $1.5 billion. The transaction, comprising 64% Repligen common stock and 36% cash, has been unanimously approved by both companies' directors and is expected to close in the fourth quarter of 2026, pending regulatory and shareholder approvals. Repligen, a global life sciences company, specializes in bioprocessing technologies for biological drug manufacturing.
BioLife Solutions Inc (BLFS) Stock Up 6.8% but GF Value Says Overvalued -- GF Score: 72/100
BioLife Solutions Inc (BLFS) shares recently rose 6.8% to $31.15, trading near its 52-week high. However, GuruFocus's GF Value™ indicates the stock is 7.7% overvalued at $28.93, with a high historical P/E ratio. Despite an above-average GF Score™ of 72/100, insider selling of $28.1 million with no purchases suggests potential risks for investors.
BioLife Solutions to Be Acquired by Repligen for $11.25 Cash Plus 0.1442 Share Per Share
BioLife Solutions has agreed to be acquired by Repligen in a definitive merger agreement. Repligen will pay $11.25 in cash plus 0.1442 shares of Repligen common stock for each outstanding BioLife share. The acquisition is expected to close in the fourth quarter of 2026, subject to various approvals and conditions, and aims to accelerate Repligen's growth and expand its cell therapy tools footprint.
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal
Repligen Corporation has announced its definitive agreement to acquire BioLife Solutions Inc. for approximately $1.5 billion in a cash and stock deal. BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, representing a 24% premium to BioLife's 90-day volume-weighted average price. The acquisition is expected to close in Q4 2026, aiming to strengthen Repligen’s presence in the cell therapy market and generate significant cost synergies and adjusted EPS accretion over the next two years.
Repligen Corporation entered into an agreement and plan of merger to acquire BioLife Solutions, Inc. for approximately $1.6 billion.
Repligen Corporation has agreed to acquire BioLife Solutions, Inc. for approximately $1.6 billion in a cash and stock deal. BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, totaling $31.00 per share. The acquisition is expected to close in the fourth quarter of 2026, subject to customary closing conditions, and is projected to be accretive to Repligen's revenue growth, margins, and adjusted EPS.
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating BioLife Solutions, Inc. (NASDAQ: BLFS) regarding a potential breach of fiduciary duty concerning its transaction with Repligen. BioLife shareholders are set to receive $11.25 in cash and 0.1442 shares of Repligen stock, totaling $31.00 per share, valuing the deal at approximately $1.5 billion. The investigation questions the fairness of this price, the benefits to insiders through change of control arrangements, and a significant penalty clause limiting competing bids.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)
Monteverde & Associates PC, a class action firm, has launched an investigation into BioLife Solutions, Inc. (NASDAQ: BLFS) regarding its proposed sale to Repligen Corporation. Shareholders are expected to receive $11.25 in cash and 0.1442 shares of Repligen stock per share. The firm is inquiring whether this is a fair deal for BioLife shareholders and is seeking to connect with concerned investors.
Press Release: Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities With Market Leading Biopreservation Media
Repligen Corporation is set to acquire BioLife Solutions to enhance its cell therapy capabilities through BioLife's biopreservation media. This strategic acquisition aims to strengthen Repligen's position in the cell and gene therapy market by integrating BioLife's market-leading solutions. The move comes as demand for advanced bioprocessing tools and technologies continues to grow within the life sciences sector.
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Repligen Corporation has announced its definitive agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to expand its leadership in the cell therapy market. This acquisition will integrate BioLife's biopreservation media platform and cell processing tools, which are critical for cell and gene therapies, into Repligen's offerings. The transaction is expected to enhance Repligen's top-line growth, adjusted margins, and adjusted earnings per share, with closing anticipated in the fourth quarter of 2026.
